L1 Capital’s Xenon Pharmaceuticals XENE Stock Holding History

L1 Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,296	Closed	-$40.6K	–	33
2025 Q2	$40.6K	Buy	+1,296	New	+$42.3K	﹤0.01%	30

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

L1 Capital's XENE Position: Q3 2025 in Review

L1 Capital sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 1,296 shares — an estimated $40.6K sold.

L1 Capital first reported a position in XENE in Q2 2025 and held it in 1 quarter. The position peaked at $40.6K in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

L1 Capital reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
L1 Capital sold 1,296 Xenon Pharmaceuticals shares in Q3 2025, an estimated $40.6K.
L1 Capital first reported a position in Xenon Pharmaceuticals in Q2 2025 and held it in 1 quarter.
L1 Capital's Xenon Pharmaceuticals position peaked at $40.6K in Q2 2025.
219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on L1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.